Tema Oncology ETF (CANC)
| Assets | $17.09M |
| Expense Ratio | 0.75% |
| PE Ratio | 26.86 |
| Shares Out | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +492.53% |
| Volume | 250 |
| Open | 26.71 |
| Previous Close | 26.61 |
| Day's Range | 26.40 - 26.72 |
| 52-Week Low | 2.89 |
| 52-Week High | 26.72 |
| Beta | n/a |
| Holdings | 46 |
| Inception Date | Aug 15, 2023 |
About CANC
Fund Home PageThe Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Top 10 Holdings
36.36% of assets| Name | Symbol | Weight |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 5.07% |
| Merck & Co., Inc. | MRK | 4.58% |
| Illumina, Inc. | ILMN | 3.75% |
| Novartis AG Registered Shares | NOVN.SW | 3.71% |
| AstraZeneca PLC | AZN.L | 3.53% |
| Daiichi Sankyo Co Ltd | 4568.T | 3.42% |
| Gilead Sciences, Inc. | GILD | 3.28% |
| ImmunoGen, Inc. | IMGN | 3.03% |
| Chugai Pharmaceutical Co Ltd | 4519.T | 3.01% |
| argenx SE | ARGX | 2.97% |
News
This Week in ETFs: 2 New Funds Launch From Tema
The U.S. ETF industry saw a major slowdown in ETF launches during the week ending Aug. 18 as the summer slump continued. Only six new ETFs launched, while issuers announced only one new closure.
Tema Launches Two Innovative, Active ETF Thematic Strategies: Oncology & Global Royalties
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”) launches two innovative and actively managed thematic ETF offerings: the Oncology ETF (CANC) and the Global Royalties ETF (ROYA). These strategies are the...